Invesco Ltd. Acquires 10,611 Shares of Annexon, Inc. (NASDAQ:ANNX)

Invesco Ltd. grew its holdings in Annexon, Inc. (NASDAQ:ANNX) by 49.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 31,881 shares of the company’s stock after purchasing an additional 10,611 shares during the quarter. Invesco Ltd.’s holdings in Annexon were worth $164,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. E Fund Management Co. Ltd. increased its holdings in Annexon by 36.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock valued at $79,000 after buying an additional 4,086 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Annexon in the 4th quarter valued at $98,000. Arizona State Retirement System bought a new position in shares of Annexon in the 4th quarter worth $102,000. Teacher Retirement System of Texas purchased a new stake in shares of Annexon during the 4th quarter worth $106,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Annexon during the fourth quarter valued at about $116,000.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of Annexon in a research report on Tuesday, March 4th.

Annexon Stock Up 6.2 %

ANNX opened at $1.97 on Monday. Annexon, Inc. has a 52-week low of $1.29 and a 52-week high of $7.85. The company has a market cap of $216.14 million, a P/E ratio of -1.88 and a beta of 1.24. The firm’s 50-day moving average price is $2.08 and its 200-day moving average price is $4.02.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, research analysts anticipate that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.